Literature DB >> 27069756

A nationwide non-interventional epidemiological data registry on myelodysplastic syndromes in Lebanon.

Zaher K Otrock1, Nabil Chamseddine2, Ziad M Salem3, Tarek Wehbe4, Mouna Al-Ayoubi5, Moussa Dhaini6, Joseph Kattan7, Walid Mokaddem8, Therese Abi Nasr9, Oussama Jradi6, Fadi S Farhat10, Mahmoud Wehbe11, Mohammad H Haidar12, Mohamed A Kharfan-Dabaja13, Nizar Bitar14, Mirna El Hajj2, Adel M Kadri15, Francois G Kamar16, Hanan Yassine17, Hassan Khodr18, Ali T Taher3, Noha Hakime19, Rami Ar Mahfouz20, Wassim Serhal21, Ali Bazarbachi3, Hussein Z Farhat21.   

Abstract

Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic disorders characterized by peripheral blood cytopenias, blood cells dysplasia, and increased risk for progression to acute leukemia.Physicians should be vigilant in diagnosing MDS and should be aware of the contemporary therapies that are always in progress. Most of the data on MDS epidemiology and management comes from developed countries. The incidence and features of MDS in the Arab countries, among them Lebanon, are not known. We undertook a nationwide epidemiological registry study of all newly diagnosed MDS cases through 2010-2011. Patients were referred by 21 hematologists/oncologists practicing in 17 hospitals and medical centers distributed across the entire country. 58 patients (29 males and 29 females) with confirmed MDS were included. The calculated incidence rate of MDS was 0.71 per 100,000 people. The median age at diagnosis was 73 years (range 16-86). The most common complaints on presentation were fatigue (70.7%), weakness (60.3%) and pallor (43.1%). Most patients were diagnosed as refractory anemia with excess blasts (RAEB; 36.2%) and refractory cytopenia with multilineage dysplasia (RCMD; 32.8%). This paper constitutes the first epidemiological report on the incidence and specific subtypes of MDS in Lebanon.

Entities:  

Keywords:  Lebanon; Myelodysplastic syndromes; diagnosis; epidemiology; features; registry

Year:  2015        PMID: 27069756      PMCID: PMC4769350     

Source DB:  PubMed          Journal:  Am J Blood Res        ISSN: 2160-1992


  20 in total

Review 1.  Myelodysplastic Syndromes: Diagnosis and Treatment.

Authors:  David P Steensma
Journal:  Mayo Clin Proc       Date:  2015-07       Impact factor: 7.616

Review 2.  Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries.

Authors:  Stuart L Goldberg; Er Chen; Mitra Corral; Amy Guo; Nikita Mody-Patel; Andrew L Pecora; Marianne Laouri
Journal:  J Clin Oncol       Date:  2010-04-26       Impact factor: 44.544

3.  Trends in incidence, initial treatment and survival of myelodysplastic syndromes: a population-based study of 5144 patients diagnosed in the Netherlands from 2001 to 2010.

Authors:  Avinash G Dinmohamed; Otto Visser; Yvette van Norden; Peter C Huijgens; Pieter Sonneveld; Arjan A van de Loosdrecht; Mojca Jongen-Lavrencic
Journal:  Eur J Cancer       Date:  2013-12-31       Impact factor: 9.162

4.  Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project.

Authors:  Milena Sant; Claudia Allemani; Carmen Tereanu; Roberta De Angelis; Riccardo Capocaccia; Otto Visser; Rafael Marcos-Gragera; Marc Maynadié; Arianna Simonetti; Jean-Michel Lutz; Franco Berrino
Journal:  Blood       Date:  2010-07-27       Impact factor: 22.113

Review 5.  Myelodysplastic syndromes: diagnosis and staging.

Authors:  Luca Malcovati; Stephen D Nimer
Journal:  Cancer Control       Date:  2008-10       Impact factor: 3.302

Review 6.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

Authors:  James W Vardiman; Jüergen Thiele; Daniel A Arber; Richard D Brunning; Michael J Borowitz; Anna Porwit; Nancy Lee Harris; Michelle M Le Beau; Eva Hellström-Lindberg; Ayalew Tefferi; Clara D Bloomfield
Journal:  Blood       Date:  2009-04-08       Impact factor: 22.113

Review 7.  Epidemiology of myelodysplastic syndromes.

Authors:  Sara S Strom; Vivianne Vélez-Bravo; Elihu H Estey
Journal:  Semin Hematol       Date:  2008-01       Impact factor: 3.851

8.  Unique cytogenetic features of primary myelodysplastic syndromes in Chinese patients.

Authors:  Lin Li; Xu-Ping Liu; Ling Nie; Ming-Hua Yu; Yue Zhang; Tie-Jun Qin; Zhi-Jian Xiao
Journal:  Leuk Res       Date:  2009-01-06       Impact factor: 3.156

9.  Myelodysplastic syndromes: incidence and survival in the United States.

Authors:  Xiaomei Ma; Monique Does; Azra Raza; Susan T Mayne
Journal:  Cancer       Date:  2007-04-15       Impact factor: 6.860

10.  Incidence, survival and prevalence of myeloid malignancies in Europe.

Authors:  O Visser; A Trama; M Maynadié; C Stiller; R Marcos-Gragera; R De Angelis; S Mallone; C Tereanu; C Allemani; U Ricardi; H C Schouten
Journal:  Eur J Cancer       Date:  2012-07-04       Impact factor: 9.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.